Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Trending News on Targeted Oncology, Week of March 27, 2020

March 27, 2020
By Danielle Ternyila
Article

Targeted Oncology reviews trending news and videos online for the week of March 27, 2020, including recent updates on the impact of COVID-19 in oncology practice and a clinical trial on breast cancer.

Experts such as Randall A. Oyer, MD, from Penn Medicine Lancaster General, and Kashyep Patel, MD, of the Carolina Blood and Cancer Center, spoke withTargeted Oncologyon the impact seen in their practices due to the COVID-19 pandemic. The Community Oncology Alliance (COA) also brought attention to concerns in the community.

Although the focus remains on COVID-19 and its impacts on oncology practice as a whole, the Annual Report to the Nation on the Status of Cancer demonstrated declines in cancer rate deaths and highlighted the importance of clinical advances.

These updates and others were trending this week:

Challenges for Clinical Trials and Treating Patients With Cancer in Light of the Coronavirus

In an interview withTargeted Oncology, Oyer discussed how his institution is handling the COVID-19 pandemic while still accommodating patients who are already enrolled on clinical trials. The opening of new trials and enrollment has been suspended at this time, but new patients may be enrolled on trials if the treatment is necessary. Precautions have been taken to keep both staff and patients safe during this time.

South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic

The spread of COVID-19 has impacted practices across the country, but Carolina Blood and Cancer Care has made adjustments to ensure the safety of their patients and staff while COVID-19 remains an issue. In an interview withTargeted Oncology, Patel discussed the implementation of new precautions in his practice as the number of COVID-19 cases rises in South Carolina.

Death By Cancer Shows Decline in the 2020 Annual Report to the Nation on the Status of Cancer

According to the Annual Report to the Nation on the Status of Cancer, which was published inCancer, cancer death rates continued to decline in the United States from 2001 to 2017 across all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016.

Additional data from the report related tothe Healthy People 2020 Initiativedemonstrated the importance of monitoring trends in cancer risk, screening test use, and mortality.

COA President Urges White House to Waive Prior Authorization Requirements for Cancer Treatment

In an open letter to the President of the United States, COA brought attention to the critical needs of patients with cancer, requesting all private health insurance companies immediately waive all “prior authorization” requirements for cancer treatments, which pose a threat to cancer treatment, particularly in patients who are elderly and among the most vulnerable in the United States to contract COVID-19.

Novel Immunotherapy Strategy Demonstrates Favorable Toxicity in Early-Stage Breast Cancer

Patients with early-stage breast cancer who received pelareorep demonstrated consistent findings with that of the safety run-in data and had a favorable toxicity profile, according to a cohort analysis from the window-of-opportunity study, AWARE-1 (NCT04102618).

Videos:

Atezolizumab and Bevacizumab Studied in Patients With Metastatic RCC

Bradley McGregor, MD, of Dana-Farber Cancer Institute, discussed a trial investigating atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with metastatic renal cell carcinoma (RCC) and variant histologies and/or sarcomatoid features.

Case Studies: A 56-Year-Old Female With Recurrent Ovarian Cancer

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
1 expert is featured in this series.
Related Content

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Jordyn Sava
June 19th 2025
Article

Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.

Read More


Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Jordyn Sava;Xiaojie Zhang, MD;Akshat Singhal, PhD
April 15th 2025
Podcast

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

Listen


Bexobrutideg: Well-Tolerated in Relapsed/Refractory CLL

Bexobrutideg: Well-Tolerated in Relapsed/Refractory CLL

Ashley Chan
June 19th 2025
Article

New data reveals bexobrutideg shows promising efficacy and safety in treating relapsed/refractory chronic lymphocytic leukemia, offering hope for patients.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Jason M. Broderick
June 18th 2025
Article

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

Read More


FDA Approves Tafasitamab in R/R Follicular Lymphoma

FDA Approves Tafasitamab in R/R Follicular Lymphoma

Jordyn Sava
June 18th 2025
Article

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.

Read More

Related Content

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Jordyn Sava
June 19th 2025
Article

Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.

Read More


Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Jordyn Sava;Xiaojie Zhang, MD;Akshat Singhal, PhD
April 15th 2025
Podcast

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

Listen


Bexobrutideg: Well-Tolerated in Relapsed/Refractory CLL

Bexobrutideg: Well-Tolerated in Relapsed/Refractory CLL

Ashley Chan
June 19th 2025
Article

New data reveals bexobrutideg shows promising efficacy and safety in treating relapsed/refractory chronic lymphocytic leukemia, offering hope for patients.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Subgroup Data Sustain Cadonilimab Survival Benefit in Cervical Cancer

Jason M. Broderick
June 18th 2025
Article

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

Read More


FDA Approves Tafasitamab in R/R Follicular Lymphoma

FDA Approves Tafasitamab in R/R Follicular Lymphoma

Jordyn Sava
June 18th 2025
Article

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.